NCT04418401 2026-02-17
CISLD-8
Zhejiang University
Phase 1 Completed
Clinical Trials
15 trialsNCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT07180459 2025-09-18
The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study
The First Affiliated Hospital of Zhengzhou University
Not yet recruiting
NCT07157306 2025-09-05
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06609876 2024-12-03
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Sun Yat-sen University
Phase NA Recruiting
NCT06581315 2024-09-03
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase NA Recruiting
NCT05262959 2024-08-13
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT06498622 2024-07-12
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
Anhui Provincial Hospital
Phase 2 Recruiting
NCT05545124 2022-09-19
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Henan Cancer Hospital
Phase 2 Unknown
NCT05507632 2022-08-19
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT05493332 2022-08-18
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05205629 2022-03-23
A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
Shanghai Zhongshan Hospital
Unknown
NCT05166772 2021-12-22
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05161143 2021-12-17
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown